| Authors: |
Owen RG; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., McCarthy H; Royal Bournemouth Hospital, Bournemouth, United Kingdom., D'Sa S; University College London Hospitals NHS Foundation Trust, London, United Kingdom., Thomas SK; MD Anderson Cancer Center, Houston, TX., Tournilhac O; Service d'Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, EA7453 CHELTER and CIC-1405, Université Clermont Auvergne, Clermont-Ferrand, France., Forconi F; Cancer Care and Cancer Sciences, Faculty of Medicine, University of Southampton Hospital Trust, Southampton, United Kingdom., Kersten MJ; Amsterdam University Medical Centers, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Iyengar S; Royal Marsden Hospital, London, United Kingdom., Kothari J; Churchill Hospital, Oxford, United Kingdom., Minnema MC; Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands., Kastritis E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Cheson BD; Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC., Walter HS; Ernest and Helen Scott Haematological Research Institute and Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom., Greenwald D; University of California, Los Angeles, Santa Barbara Cancer Center, Santa Barbara, CA., Calvo R; AstraZeneca, Gaithersburg, MD., Li Y; AstraZeneca, South San Francisco, CA., Rule S; AstraZeneca, Mississauga, ON, Canada., Furman RR; Division of Hematology and Oncology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY. |
